Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

Bibliographic Details
Main Authors:	Esaki, Taito, Seto, Takashi, Ariyama, Hiroshi, Arita, Shuji, Fujimoto, Chinatsu, Tsukasa, Koichiro, Kometani, Takuro, Nosaki, Kaname, Hirai, Fumihiko, Yagawa, Katsuro
Format:	Online
Language:	English
Published:	Blackwell Publishing Inc 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130141/

Similar Items

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
by: Tamura, Kenji, et al.
Published: (2016)

Burden on Oncologists When Communicating the Discontinuation of Anticancer Treatment
by: Otani, Hiroyuki, et al.
Published: (2011)

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer
by: Nosaki, Kaname, et al.
Published: (2015)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
by: Naing, A, et al.
Published: (2012)

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
by: Niazi, Mohammad, et al.
Published: (2012)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
by: Shimizu, Toshio, et al.
Published: (2016)

Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia
by: Genovese, Giulio, et al.
Published: (2016)

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABAB-Receptor Agonist Reflux Inhibitor
by: Niazi, Mohammad, et al.
Published: (2012)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)
by: Bjermer, Leif, et al.
Published: (2015)

Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists
by: Kindon, Nicholas, et al.
Published: (2017)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
by: Yonemori, Kan, et al.
Published: (2016)

AZD9291-induced Acute Interstitial Lung Disease
by: Nie, Ke-Ke, et al.
Published: (2016)

Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer’s disease patients
by: Forsberg, Anton, et al.
Published: (2013)

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
by: Dennis, Mike, et al.
Published: (2012)

Activity of the aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia
by: Grundy, Martin
Published: (2012)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
by: Derenzini, E, et al.
Published: (2011)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
by: Derenzini, E, et al.
Published: (2014)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
by: CRAFTER, CLAIRE, et al.
Published: (2015)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
by: Harada, Masako, et al.
Published: (2015)

Computational performance of Free Mesh Method applied to continuum mechanics problems
by: YAGAWA, Genki
Published: (2011)

Free Mesh Method: fundamental conception, algorithms and accuracy study
by: YAGAWA, Genki
Published: (2011)

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock
by: Morris, Peter E, et al.
Published: (2012)

Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
by: Stocks, Michael, et al.
Published: (2014)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
by: Kaye, S, et al.
Published: (2012)

AZD9773 is a novel and potent anti-TNFα polyclonal ovine immune Fab
by: Newham, P, et al.
Published: (2011)

Safety and tolerability of an ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773) in patients with severe sepsis
by: Morris, P, et al.
Published: (2011)

18F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
by: Desar, Ingrid M. E., et al.
Published: (2012)

The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
by: LI, SHAORU, et al.
Published: (2013)

AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
by: Couto, Joana P., et al.
Published: (2012)

Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study
by: Kuna, Piotr, et al.
Published: (2013)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
by: Guido Fròsina, et al.
Published: (2018-04-01)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
by: Checkley, Stephen, et al.
Published: (2015)

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
by: Kuna, Piotr, et al.
Published: (2016)

Propofol and AZD3043 Inhibit Adult Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes
by: Jonsson Fagerlund, Malin, et al.
Published: (2016)

Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer
by: Chen, Shuo, et al.
Published: (2016)

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
by: Yasukawa, Masaaki, et al.
Published: (2016)

Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas
by: Kreuz, S., et al.
Published: (2015)

AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair
by: Ford, James B., et al.
Published: (2015)

AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor
by: Cederblad, Linda, et al.
Published: (2016)

Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
by: Delaney, Stephen, et al.
Published: (2016)